Four patients developed hypothyroidism with the absence of a precedent thyrotoxic phase 6–8 weeks after anti-PD-1 mAbs initiation, characterized by positive antithyroid antibodies and a necessity for thyroid hormone replacement therapy for a minimum of 6 months [57]. This evidence concerns the gene TG and hypothyroidism.